DrugCombination product
Anifrolumab clinical trials
Also written MEDI-546 and Saphnelo.
- studies test it
- 32
- open now
- 10
- in phase 3
- 13
- first study started
- 2009
Keep track of what changes. Save the anifrolumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
32 studies that test it; most in 2026 (7)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 5 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 12
- Phase 3
- 13
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 7
AstraZeneca (22) · MedImmune LLC (3) · University of North Carolina, Chapel Hill (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · National and Kapodistrian University of Athens (1) · University Hospital, Bordeaux (1) · Oklahoma Medical Research Foundation (1) · University Medical Center Groningen (1)
Studies
Open first, then newest update. How each study uses anifrolumab is read from its arms, and is right about nine times in ten.
Testing it · 32
- A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus ErythematosusRecruitingPhase 3AstraZenecaNCT07751848Written as Anifrolumab
- Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued TreatmentRecruitingPhase 3AstraZenecaNCT07691970Written as Anifrolumab
- An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsRecruitingPhase 3AstraZenecaNCT05835310Written as Anifrolumab
- A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusRecruitingPhase 3AstraZenecaNCT07430306Written as Anifrolumab
- A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)RecruitingPhase 3AstraZenecaNCT06455449Written as Anifrolumab (blinded)
- A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus ErythematosusRecruitingPhase 2AstraZenecaNCT07630714Written as Anifrolumab + APFS
- The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVDRecruitingPhase 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT05440422Written as anifrolumab
- Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersRecruitingPhase 4AstraZenecaNCT06594068Written as Anifrolumab
- Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)Not yet recruitingPhase 1AstraZenecaNCT07688980Written as Anifrolumab: SC formulation via AI
- Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)RecruitingPhase 2National and Kapodistrian University of AthensNCT07584083Written as Anifrolumab
- Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)Active, not recruitingPhase 3AstraZenecaNCT05925803Written as Anifrolumab (blinded)
- Anifrolumab for Hidradenitis SuppurativaCompletedPhase 2University of North Carolina, Chapel HillNCT06374212Written as Anifrolumab
- Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisActive, not recruitingPhase 3AstraZenecaNCT05138133Written as Anifrolumab
- A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusActive, not recruitingPhase 3AstraZenecaNCT06015737Written as Anifrolumab
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus ErythematosusActive, not recruitingPhase 3AstraZenecaNCT04877691Written as Medi-546
- Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)CompletedPhase 3AstraZenecaNCT04931563Written as Anifrolumab
- Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult ParticipantsCompletedPhase 1AstraZenecaNCT06662123Written as Anifrolumab
- Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive VitiligoStatus unknownPhase 2University Hospital, BordeauxNCT05917561Written as Anifrolumab Infusion Product
- Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLEStatus unknownEarly Phase 1Oklahoma Medical Research FoundationNCT04726553Written as Anifrolumab
- Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus ErythematosusCompletedPhase 3AstraZenecaNCT02794285Written as Anifrolumab
See all 32 studies that test anifrolumab →
Given in every arm · 1 — anifrolumab is usual care beside what is tested
Codes
What other systems call anifrolumab · ClinicalTrials.gg INT006312
- MeSH (NLM) C582345anifrolumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 38RL9AE51QANIFROLUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2565265One source FDA
- Wikidata Q15708296AnifrolumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166658AnifrolumabOne source FDA
- DrugBank DB78910One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C582345 | anifrolumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 38RL9AE51Q | ANIFROLUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2565265 | — | One source FDA |
| Wikidata | Q15708296 | Anifrolumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166658 | Anifrolumab | One source FDA |
| DrugBank | DB78910 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.